BAXTER/HYLAND GAMMIGARD S.D. AVAILABLE FOR "EMERGENCY EXEMPT USE"
BAXTER/HYLAND GAMMIGARD S.D. AVAILABLE FOR "EMERGENCY EXEMPT USE" following the firm's worldwide voluntary withdrawal of Gammigard due to the product's "possible association with hepatitis C virus," Baxter told physicians in a Feb. 23 "Dear Doctor" letter. The letter instructs physicians who need to treat patients who require intravenous immunoglobulin with low IgA to "apply for emergency exempt use of Baxter's virally-inactivated investigation[al] product by contacting the company at 1- 800-423-2090."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth